Patient's Whole Process Follow-up Management(HOPE-1)

Metastatic NSCLC Clinical Trial

— HOPE-1  

Official title:

A Multicenter, Randomized, Open, Parallel Grouping, Investigator-initiated Study Evaluating the Long-term Benefit of Patients With Locally Advanced/Metastatic Non-small Cell Lung Cancer Followed up Using a Patient-wide Management Platform

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05339568
• Other study ID #: WYKA001
• Status: Recruiting
• Start date: May 22, 2022
• Est. completion date: August 20, 2030

Study information

• Verified date: September 2022
• Source: Qianfoshan Hospital
• Contact: Jiandong ZHANG
• Phone: (+86531)89268118
• Email: zhangjd165[@]sina.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

Description:

Now, the treatment of NSCLC is diversiform, such as radiation and chemotherapy, targeted therapy, immune therapy, the treatment goal is to reduce symptoms, improve quality of life, prolong life. But as a result of the disease itself has the high risk of metastasis and recurrence. The treatment is often accompanied by a series of complications, if the patients don't get medical assistance in time, it will lead high risk to physical and mental health of patients. In China, the intermittent period of domestic treatment is mainly family recuperation, but due to the lack of medical knowledge or self-management and self-restraint ability of patients, they may forget to take medicine, stop medication without permission due to side effects and other behaviors that do not follow the doctor's advice, the poorly patients' compliance will lead to a significant reduction in the treatment effect. NSCLC are often accompanied by anxiety, fear, insomnia and other symptoms, causing a huge psychological burden on patients and their families, affecting the quality of life. Whole process follow-up in tumor therapy plays an important role , it is the crucial link between medical, nursing, and patients. Patients' whole process follow-up and management is an important part of cancer disease management.

It is helpful to relieve the patients and their families of the bad psychology, reduce the symptoms of patients, improve the patient's compliance behavior, relieve the psychological anxiety of patients, make it actively cooperate with the treatment, reduce complications, improve the quality of life of patients, so as to prolong the life cycle.

Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1268
• Est. completion date: August 20, 2030
• Est. primary completion date: April 21, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Fully understand the research and voluntarily sign the informed consent form (ICF)

2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.

3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).

4. According to the 8th edition of the American Joint Committee on Cancer [AJCC], it is classified as stage IIB, stage III, stage IV NSCLC.

5. Not suitable for radical treatment or refuse surgery.

6. The life expectancy is not less than 3 months.

7. Be able to use a smartphone.

Exclusion Criteria:

1. Patients with mental illness.

2. Presence of any other malignant tumor.

3. Patients who are expected to undergo radical surgery.

4. Currently participating in clinical trials.

5. Subjects who judged by the investigator to be unsuitable to participate in the trial.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Locally Advanced Non-Small Cell Lung Cancer
• Lung Neoplasms
• Metastatic NSCLC

Intervention

Other:
• Patients' whole process follow-up and management platform
Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Shandong First Medical University	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qianfoshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival time	OS was calculated from the date of randomization to death from any cause.	UP to 96 months
Secondary	Progression-free survival (PFS)	PFS was calculated from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months.	Up to 96 months
Secondary	Adverse events rate	Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.	Up to 96 months
Secondary	Patients' follow-up compliance	Patients' follow-up compliance were assessed by the N of hospital visits according to the doctors' advice every year.	Up to 96 months
Secondary	The quality of life	The quality of life were assessed by SF-36,The SF-36 questionnaire consists of 8 section, including physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health, also including reported health transition. The scoring steps: 1 encode the scale 2 credit the scale 3 score conversion(conversion formula=(actual score-the possible lowest score of this section)/the difference between the possible highest score and the possible lowest score of this section).The higher the score conversion, the better the health.	Up to 96 months
Secondary	Follow-up satisfaction	Follow-up satisfaction were assessed by the questionnaire. The questionnaire is including 12 questions, where 28 is the worst imaginable satisfaction state and 130 is the best imaginable satisfaction state.	Up to 96 months